Merck KGaA 향후 성장
Future 기준 점검 1/6
Merck KGaA (는) 각각 연간 8.9% 및 4.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.7% 로 예상됩니다.
핵심 정보
8.9%
이익 성장률
8.98%
EPS 성장률
| Pharmaceuticals 이익 성장 | 24.0% |
| 매출 성장률 | 4.4% |
| 향후 자기자본이익률 | 12.66% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 05 Jul 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Jul 06
MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside
Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.내러티브 업데이트 • Jun 22
MRK: Life Science Tools Recovery Will Support Future Upside Potential
Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.내러티브 업데이트 • Jun 06
MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside
Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
내러티브 업데이트 • May 23
MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside
Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.내러티브 업데이트 • Apr 30
MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside
The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
내러티브 업데이트 • Apr 15
MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance
Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.내러티브 업데이트 • Apr 01
MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside
Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.내러티브 업데이트 • Mar 18
MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside
Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.내러티브 업데이트 • Mar 04
MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside
Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.내러티브 업데이트 • Feb 18
MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential
Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.내러티브 업데이트 • Feb 03
MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential
Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.내러티브 업데이트 • Jan 20
MRK: Refined Earnings Outlook Points To Balanced Future Return Potential
Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.내러티브 업데이트 • Jan 06
MRK: Future Earnings Power And HPC Expansion May Support Upside
Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.내러티브 업데이트 • Dec 21
MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead
Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.내러티브 업데이트 • Dec 07
MRK: Margin Strength And AI Deal Will Drive Future Upside
Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.내러티브 업데이트 • Nov 23
MRK: New Leadership Change And AI Partnership Will Drive Shares Higher
Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.내러티브 업데이트 • Nov 03
MRK: Future CEO Appointment Will Support Recovery and Restore Confidence
The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.내러티브 업데이트 • Oct 20
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.내러티브 업데이트 • Sep 04
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.분석 기사 • Jul 24
We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
새로운 내러티브 • Nov 24
AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights
Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 23,268 | 3,216 | 3,175 | 4,953 | 12 |
| 12/31/2027 | 22,050 | 2,907 | 2,921 | 4,639 | 13 |
| 12/31/2026 | 21,056 | 2,538 | 2,712 | 4,569 | 14 |
| 3/31/2026 | 20,956 | 2,532 | 2,419 | 4,194 | N/A |
| 12/31/2025 | 21,102 | 2,608 | 2,145 | 3,932 | N/A |
| 9/30/2025 | 21,271 | 2,956 | 2,103 | 3,872 | N/A |
| 6/30/2025 | 21,219 | 2,862 | 1,800 | 3,813 | N/A |
| 3/31/2025 | 21,316 | 2,818 | 2,184 | 4,107 | N/A |
| 12/31/2024 | 21,156 | 2,777 | 2,420 | 4,586 | N/A |
| 9/30/2024 | 20,963 | 2,696 | 2,160 | 4,408 | N/A |
| 6/30/2024 | 20,870 | 2,626 | 2,052 | 4,205 | N/A |
| 3/31/2024 | 20,820 | 2,722 | 1,961 | 3,966 | N/A |
| 12/31/2023 | 20,993 | 2,824 | 1,897 | 3,784 | N/A |
| 9/30/2023 | 21,428 | 2,893 | 1,912 | 3,746 | N/A |
| 6/30/2023 | 22,061 | 3,078 | 2,198 | 4,042 | N/A |
| 3/31/2023 | 22,327 | 3,242 | 2,334 | 4,272 | N/A |
| 12/31/2022 | 22,232 | 3,326 | 2,491 | 4,259 | N/A |
| 9/30/2022 | 21,785 | 3,473 | 2,788 | 4,289 | N/A |
| 6/30/2022 | 20,952 | 3,311 | 2,658 | 4,204 | N/A |
| 3/31/2022 | 20,254 | 3,188 | 2,734 | 4,240 | N/A |
| 12/31/2021 | 19,687 | 3,055 | 3,234 | 4,616 | N/A |
| 9/30/2021 | 19,072 | 2,689 | 3,125 | 4,859 | N/A |
| 6/30/2021 | 18,546 | 2,733 | 3,073 | 4,562 | N/A |
| 3/31/2021 | 17,795 | 2,278 | 2,702 | 4,177 | N/A |
| 12/31/2020 | 17,534 | 1,987 | 2,002 | 3,477 | N/A |
| 9/30/2020 | 17,317 | 1,884 | 1,684 | 2,879 | N/A |
| 6/30/2020 | 16,924 | 1,419 | 1,498 | 2,640 | N/A |
| 3/31/2020 | 16,776 | 1,549 | 1,729 | 2,879 | N/A |
| 12/31/2019 | 16,152 | 1,292 | N/A | 2,856 | N/A |
| 9/30/2019 | 15,658 | 1,139 | N/A | 2,906 | N/A |
| 6/30/2019 | 15,354 | 1,118 | N/A | 2,706 | N/A |
| 3/31/2019 | 15,096 | 938 | N/A | 2,332 | N/A |
| 12/31/2018 | 14,836 | 1,071 | N/A | 2,219 | N/A |
| 9/30/2018 | 14,597 | 1,921 | N/A | 2,120 | N/A |
| 6/30/2018 | 14,364 | 2,218 | N/A | 2,147 | N/A |
| 3/31/2018 | 14,346 | 2,389 | N/A | 2,299 | N/A |
| 12/31/2017 | 14,517 | 2,548 | N/A | 2,696 | N/A |
| 9/30/2017 | 14,699 | 1,787 | N/A | 2,842 | N/A |
| 6/30/2017 | 14,906 | 1,628 | N/A | 3,152 | N/A |
| 3/31/2017 | 15,016 | 1,529 | N/A | 2,943 | N/A |
| 12/31/2016 | 15,024 | 1,629 | N/A | 2,518 | N/A |
| 9/30/2016 | 14,658 | 1,480 | N/A | 2,449 | N/A |
| 6/30/2016 | 14,054 | 1,387 | N/A | 2,253 | N/A |
| 3/31/2016 | 13,469 | 1,418 | N/A | 2,268 | N/A |
| 12/31/2015 | 12,845 | 1,109 | N/A | 2,195 | N/A |
| 9/30/2015 | 12,380 | 1,269 | N/A | 2,618 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: MRK 의 연간 예상 수익 증가율(8.9%)이 saving rate(1.9%)보다 높습니다.
수익 vs 시장: MRK 의 연간 수익(8.9%)이 German 시장(17.1%)보다 느리게 성장할 것으로 예상됩니다.
고성장 수익: MRK 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: MRK 의 수익(연간 4.4%)이 German 시장(연간 6.8%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: MRK 의 수익(연간 4.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: MRK의 자본 수익률은 3년 후 12.7%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/07 22:18 |
| 종가 | 2026/07/07 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Merck KGaA는 42명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Charles Pitman | Barclays |